AMGN241122C415000
- 0.05
- 0.000.00%
Amgen Newsroom
Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Viking Therapeutics a New Buy at B Riley on Lead Obesity Asset VK2735
Astrazeneca (AZN.US) and Amgen (AMGN.US) announced the domestic application for the subcutaneous injection of TSLP monoclonal antibody.
CDE's official website shows that astrazeneca (AZN.US) and amgen (AMGN.US) jointly submitted the marketing application for the TSLP monoclonal antibody Tezepelumab injection.
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Amgen (AMGN.US) weight loss drug is poised for launch, and Wall Street is eagerly awaiting the research results.
The upcoming data from Amgen's experimental weight loss drug MariTide mid-term study will reveal the comparison of this drug with the GLP-1 drugs sold by Eli Lilly and Co and Novo-Nordisk A/S.
Optimism Over Global Healthcare Sector Rises: Jefferies
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Sticks to Their Buy Rating for Amgen (AMGN)
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Amgen: Chang Appointment Effective Dec. 16 >AMGN
Express News | Amgen Announces Senior Executive Research Appointment
Amgen Names Howard Chang as Scientific Chief >AMGN
UnitedHealth, Amgen Share Gains Lead Dow's 114-Point Climb
Decoding Amgen's Options Activity: What's the Big Picture?
Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $335
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Unusual Options Activity: TEVA, MDT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 322.6
EST Nov 18th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.